

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Takashi Shoda, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshio Takahashi, Corporate Officer in Charge,
Corporate Communications Department
Telephone: +81-3-6225-1126
<http://www.daiichisankyo.co.jp/>

**Daiichi Pharmaceutical Korea to Become Wholly Owned Subsidiary of
Daiichi Pharmaceutical Co., Ltd.**

Tokyo, October 10, 2006 – DAIICHI SANKYO COMPANY, LIMITED has announced that its subsidiary Daiichi Pharmaceutical Co., Ltd. (President: Kiyoshi Morita, hereafter Daiichi Pharmaceutical), has signed an agreement to acquire 100% of shares in Daiichi Pharmaceutical Korea Co., Ltd. (headquarters: Seoul, hereafter KDP), a joint venture with Jeil Pharmaceutical Co., Ltd. (headquarters: Seoul, President: Sung Suk-Je, hereafter Jeil Pharmaceutical). The acquisition will take effect on October 13, when KDP becomes a wholly owned Daiichi Pharmaceutical subsidiary.

By making KDP a wholly owned subsidiary of Daiichi Pharmaceutical, the DAIICHI SANKYO Group plans to actively expand its business operations throughout Asia.

KDP Profile

Company name: Daiichi Pharmaceutical Korea Co., Ltd.
President: Kenji Morisaki
Headquarters: 3F, Seongbo Yeoksam Building, #833-2, Yeoksam-dong,
Kangnam-ku, Seoul, Korea
Established: July 16, 1990
Capital: 3 billion won
Shareholding: Daiichi Pharmaceutical 70%, Jeil Pharmaceutical 29% and an
individual shareholder 1%

Sales: 13.171 billion won (fiscal 2005)
Employees: 51 (as of March 31, 2006)
Main brands: Cravit, Neuer, Transamin